Of the 62 tumor samples available for genomic DNA sequencing, 38.7% had a KRAS mutation and 61.4% had wild-type KRAS. Wild-type KRAS was significantly associated with response to panitumumab (p = 0.0028). This evidence concerns the gene KRAS and neoplasm.